Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (19)

2023

  1. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

    The Lancet Oncology, Vol. 24, Núm. 11, pp. 1252-1265

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

2018

  1. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies

    Expert Opinion on Drug Safety, Vol. 17, Núm. 6, pp. 573-579

  2. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286

  3. Radium-223 international early access program: Results from the Spanish subset

    Future Oncology, Vol. 14, Núm. 1, pp. 41-50

2017

  1. Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer

    European Urology Focus, Vol. 3, Núm. 2-3, pp. 280-286

  2. HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma

    OncoTargets and Therapy, Vol. 10, pp. 4635-4643

  3. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

    Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421

  4. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment

    Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190

2016

  1. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations

    Targeted Oncology, Vol. 11, Núm. 2, pp. 129-141

2015

  1. Management of the adverse events of afatinib: A consensus of the recommendations of the Spanish expert panel

    Future Oncology, Vol. 11, Núm. 2, pp. 267-277

2014

  1. Cabazitaxel for metastatic castration-resistant prostate cancer: Safety data from the Spanish expanded access program

    Expert Opinion on Drug Safety, Vol. 13, Núm. 9, pp. 1165-1173

2013

  1. Dolor como factor predictor de depresión en el paciente oncológico: estudio de casos y controles. Estudio D-PRESS

    Revista de la Sociedad Espanola del Dolor, Vol. 20, Núm. 3, pp. 113-121

2012

  1. Recommendations for the optimal management of early and advanced urothelial carcinoma

    Cancer Treatment Reviews, Vol. 38, Núm. 5, pp. 431-441

2010

  1. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations

    Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1

  2. Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma

    Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1

2009

  1. Recommendations from the Spanish oncology genitourinary group for the treatment of metastatic renal cancer

    Cancer Chemotherapy and Pharmacology

2007

  1. Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas

    Cancer Chemotherapy and Pharmacology, Vol. 59, Núm. 2, pp. 251-259

2004

  1. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation

    Cancer, Vol. 101, Núm. 10, pp. 2261-2269